Garvan News Potential for earlier diagnosis of ovarian cancerMEDIA RELEASE: 24 Jan 2012 Garvan scientists have identified biochemical changes that commonly occur in the DNA of women with ovarian cancer, which may help diagnose the cancer at an earlier stage in the future. The study used whole genome DNA profiling methods - locating six potential 'biomarkers', one of them a novel gene. MoreFighting illnesses that accompany the latest anti-psychotic drugsMEDIA RELEASE: 11 Jan 2012 Anti-psychotic drugs for treating serious mental illnesses, such as bipolar disorder or schizophrenia, are effective and often life-saving but come with unwelcome side effects. They dramatically increase weight as well as the incidence of metabolic disorders such as raised blood fats and Type 2 diabetes, say Sydney-based specialists. The rapid decline in physical health is so clinically significant, and of such concern, that the specialists put together a physical health protection algorithm last year. MoreProfessor John Shine wins Peter Wills Medal05 Dec 2011 Professor John Shine AO FAA, Executive Director of Garvan, has received the inaugural Peter Wills Medal, created by Research Australia “to recognise an outstanding contribution to building Australia’s national and international reputation in the realm of health and medical research”. MoreGarvan scientist wins NHMRC prize for “highly innovative” proposals01 Dec 2011 Garvan Neuroscientist Dr Greg Neely has just won the new National Health and Medical Research Council (NHMRC) ‘Marshall and Warren Project Grant Award’, created to recognise the “best highly innovative and potentially transformative grant” from the 2011 Project Grants funding round. MoreDeconstructing diabetes – why one size does not fit allMEDIA RELEASE: 30 Nov 2011 Professor David James, Head of the Diabetes and Obesity Program at Garvan, believes it’s time to draw attention to the many things we don’t yet know about the complex metabolic disease we call ‘Type 2 diabetes’, and to the oversimplifications that abound in discussion of future treatments. MoreRomain Rouet wins 2011 Castle Harlan Award09 Nov 2011 Romain Rouet has received the $10,000 USD Castle Harlan Award for being the most outstanding early career PhD student at the Garvan Institute in 2011. Castle Harlan Inc. is a US-based private equity firm that wishes to support the kind of medical research being undertaken at Garvan. MoreA step towards preventing ‘bone failure’ in Australia07 Nov 2011 In collaboration with pharmaceutical companies and other stakeholders, Garvan will be running awareness-raising seminars about ‘bone failure’, with separate sessions for members of the public and GPs. The program, known as Health Education for Longer Life in Osteoporosis (HELLO) has its inaugural sessions on 26 and 27 November. Her Excellency Ms Quentin Bryce AC, Governor General of Australia, will be opening the Patient Seminar on 27 November. MoreUnderstanding kiss of death for some improves outlook for othersMEDIA RELEASE: 02 Nov 2011 Although we don’t realize it, almost all of us are exposed to Epstein Barr Virus (EBV), often through kissing. Around 10-20% of those exposed will develop glandular fever, known colloquially as “kissing disease”. For those born with the rare immunodeficiency known as X-linked lymphoproliferative disease (XLP), infection with the saliva-borne virus can be fatal. Garvan immunologists have discovered why EBV is so catastrophic for people with XLP. While their finding does not point to a cure, it tells us much we need to know about viruses and the immune system. More |
Events Epigenetics Presentation07 Feb 2012
Public Seminar
Australian Pancreatic Cancer Genome Initiative Meeting10 Mar 2012
Public Seminar
THE IMMUNE SYSTEM29 Mar 2012
Public Seminar
The Pituitary Gland: where are we in 2012? A public seminar presented by Garvan and the Australian Pituitary Foundation Ltd. NAB Auditorium, Garvan Institute, Saturday 25 February 2012 Registration essential - click here to download form. Garvan Links TOUR GARVAN
FRACTURE RISK CALCULATORBased on data from the 18-year Dubbo Osteoporosis Epidemiology Study. For men and women 60 years and over to assess their individual risk of fracture. www.fractureriskcalculator.com
AUSTRALIAN PANCREATIC CANCER GENOME INITIATIVEGarvan is involved in the Australian arm of the The International Cancer Genome Consortium – by investigating pancreatic cancer. For more information click here. |
